

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Entecavir for the treatment of chronic hepatitis B

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Bristol-Myers Squibb Pharmaceuticals Ltd (entecavir) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • British Liver Trust • Hepatitis B Foundation UK • South Asian Health Foundation <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Clinical Microbiologists • Association of Medical Microbiologists • British Association for the Study of the Liver • British Infection Society • British Society of Gastroenterology • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • Welsh Assembly Government 	<p><u>General</u></p> <ul style="list-style-type: none"> • Department of Health, Social Services and Public Safety for Northern Ireland • NHS Quality Improvement Scotland <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Gilead Sciences (adefovir dipivoxil) • Roche Products Limited (interferon alfa 2a, peginterferon alfa 2a) • Schering-Plough Ltd (interferon alfa 2a, interferon alfa 2b) • Novartis Pharmaceuticals UK Ltd (telbivudine) <p><u>Relevant research groups</u></p> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Southampton Health Technology Assessment Centre (SHTAC) • National Coordinating Centre for Health Technology Assessment <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Women and Children's Health <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • (None)

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

National Institute for Health and Clinical Excellence

Matrix of consultees and commentators for the appraisal of entecavir for the treatment of chronic hepatitis B

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

Manufacturer table

The matrix lists the manufacturers who have been invited to participate in a technology appraisal. As an appraisal progresses the matrix may not necessarily list all the relevant products relating to it (as manufacturers may decide that they do not wish to be involved).

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

This table has been produced to capture all the related products for easy identification of interests for anyone involved in the topic.

Consultees	
Manufacturer	Generic Name
Bristol-Myers Squibb Pharmaceuticals Ltd	entecavir
Commentators	
Manufacturer	Generic Name
Gilead Sciences	adefovir dipivoxil
GlaxoSmithKline	lamivudine
Roche Products Limited	interferon alpha 2a, peginterferon alfa 2a
Schering-Plough Ltd	interferon alfa 2a, interferon alfa 2b
Novartis Pharmaceuticals UK Ltd	telbivudine